What it is
Using transcriptomics, proteomics, metabolomics and multiplexed imaging, researchers tracked the immune response of a living patient carrying a CRISPR-engineered pig kidney, part of a program that reached a record 271-day human xenograft survival with donor organs carrying up to 69 gene edits. Despite profound depletion of circulating T cells, early T cell-mediated rejection appeared within 1 week, driven by residual CD8+ T cells in lymph nodes, and was reversed with intensified immunosuppression. Rising donor-derived cell-free DNA tracked the rejection episode and fell with treatment, while innate immune activity (monocytes, macrophages, IL-1 beta, GM-CSF) persisted even after adaptive immunity was suppressed.
Why it matters
Xenotransplantation could ease the chronic shortage of human donor organs. This is among the first detailed mechanistic immune roadmaps of a gene-edited pig organ functioning inside a living human, showing that rejection resembles human allograft rejection but carries distinct innate immune signatures. The study already carries a field-weighted citation impact near 138, underscoring its landmark status as formal trials begin.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underxenotransplantation, gene-edited pig kidney, transplant immunology, CRISPR, cell-free DNA